GlassScriptPhysician profile
Martin B Hyzinski
NPI 1467446112
$2,234.43
in general payments reported to CMS, 2019-2025
21 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $114 · 2021: $823 · 2022: $400 · 2023: $295 · 2024: $156 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $417 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $416.64 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,446.01 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $124.37 | 2019-2025 | Opdivo |
| Abbvie INC. | $104.17 | 2024-2025 | |
| Emd Serono, INC. | $86.09 | 2019-2023 | Tepmetko |
| Pharmacyclics LLC, An Abbvie Company | $77.68 | 2019-2023 | Imbruvica |
| Astellas Pharma US INC | $69.32 | 2019-2020 | |
| Incyte Corporation | $35.27 | 2024 | Jakafi |
| Kite Pharma, INC. | $33.68 | 2020-2022 | |
| Janssen Biotech, INC. | $29.92 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $29.31 | 2019 | |
| Celgene Corporation | $28.97 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $28.80 | 2020-2024 | |
| Genzyme Corporation | $24.45 | 2023 | |
| Pfizer INC. | $23.92 | 2019 | |
| Merck Sharp & Dohme LLC | $20.71 | 2023 | Keytruda |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $16.16 | 2023 | Injectafer |
| Genentech USA, INC. | $14.35 | 2021 | |
| Gilead Sciences, INC. | $14.29 | 2019 | |
| Myovant Sciences INC. | $13.81 | 2021 | |
| Seagen INC. | $13.15 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Hyzinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.